Biohaven reports Q2 non-GAAP EPS ($1.63), consensus ($1.57)

Cash, cash equivalents, marketable securities and restricted cash as of June 30 totaled approximately $408.2M. Vlad Coric, Chairman and CEO of Biohaven (BHVN), commented, “As we eagerly await a regulatory decision on the VYGLXIA,. or troriluzole, NDA for spinocerebellar ataxia, Biohaven has made important progress on multiple clinical stage assets this quarter, highlighted by the momentum we showcased at our recent R&D Day, where we unveiled advancements across our innovative therapeutic platforms.” Coric added, “We are excited about the prospects of launching the first treatment for SCA if VYGLXIA is approved by the FDA and our commercial team is taking the appropriate steps to ensure an efficient launch to meet this high unmet need. We are also enthusiastic about the progress made across our Inflammation and Immunology platform where we have observed compelling evidence of targeted protein degradation with our MoDE and TRAP degraders, BHV-1300 and BHV-1400. The body of evidence we have presented to date, combined with the safety profiles observed and convenient subcutaneous administration, continues to support our belief in our degrader platform’s ultimate potential in addressing a range of immune-mediated diseases.”